Abstract
We report on a 37-year-old female patient with generalised giant-cell tumour of the bone, whose tumour was refractory to conventional chemotherapy. Subsequent treatment with interferon α2a in increasing dosage from 4×106 IU (three times a week) to 9×106 IU (three times a week) led to a significant decrease of pulmonary metastases and a stabilisation of the disease after 12 months of treatment. In progressive chemotherapy refractory giant-cell tumour interferon α2a may be of therapeutic benefit.
Key words: Giant cell tumour, Interferon α
References
- Beresford JN, Taylor GT, Triffit JT (1990) Interferons and bone. Eur J Biochem 193:589–597 [DOI] [PubMed] [Google Scholar]
- Bertoni F, Present D, Sudanese A, Baldindi N, Bacchini P, Campanacci M (1988) Giant cell tumor of bone with pulmonary metastases. Clin Orthop 237:275–285 [PubMed] [Google Scholar]
- Komiya S, Sasaguri Y, Inoue A, Nakashima M, Yamamoto S, Yanagida I, Morimatsu M (1990) Characterization of cells cultured from human giant-cell tumors of bone. Clin Orthop 258:304–309 [PubMed] [Google Scholar]
- Strander H, Boethius J, Erhardt K, Haglund S, Hindmarsh T, Johansson B, Nilsonne U, Szamost A (1987) Does successful interferon treatment of tumor patients require life-long therapy. J Interferon Res 7:619–626 [DOI] [PubMed] [Google Scholar]
- Strander H, Bauer HCF, Brosjao O, Brostrom LA, Einhorn S, Nilsonne U, Nilsson OS (1988) Osteosarcoma management and interferon. In: Revell M (ed) Clinical aspects of interferon. Kluwer, pp 165–181
- Tischler H-J, Freund M, Harstrick A, Schober C, Poliwoda M, Schmoll H-J (1989) Recombinant interferon alpha-2b in patients with advanced osteosarcoma after agressive chemotherapy. Blut 59:322 [Google Scholar]
- Yoshida H, Akeho M, Yumoto T (1982) Giant cell tumor of bone. Virchows Arch [A] 395:319–330 [DOI] [PubMed] [Google Scholar]